-

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (888) 256-1007 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 7680382. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins.

Hologic will provide a live and webcast replay of the call on the Company’s website at www.investors.hologic.com. The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Hologic, Inc.

NASDAQ:HOLX

Release Summary
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
Release Versions
$Cashtags

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
More News From Hologic, Inc.

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference...

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software...

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.